If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Restrictive Type: In the most recent months leading up to the evaluation, the patient has not engaged in binging and purging via laxative or diuretic abuse, enemas, or self-induced vomiting. The weight loss accomplished in this patient is mainly through the use of one or more of the following methods: fasting, dieting, and excessive exercise. Binge-eating / Purging Type: In the last few months, the patient has recurrently engaged in binge-purge cycles.
The Financial Times reported that the US pushed Pakistan to broker a temporary ceasefire in early April. The next ceasefire proposal was introduced on 5 April, amidst threats from US president Trump to destroy Iranian power plants and bridges if Iran did not re-open the Strait of Hormuz. It was reportedly negotiated between Pakistani army staff chief Asim Munir, US vice president JD Vance, US special envoy Steve Witkoff, and Iranian foreign minister Abbas Araghchi. On 7 April, Trump threatened that "A whole civilization will die tonight, never to be brought back", if Iran did not reach an agreement with the US. On 21 April, Trump announced that the US was extending the ceasefire with Iran pending negotiations, while instructing the naval blockade to remain in place and telling the military to remain prepared to resume fighting. However, Axios reported that Trump does not intend to extend the ceasefire for more than a few days. On June 11, Trump announced that a ceasefire for further 60 days was reached, that would enable the parties to negotiate all the contentious issues for a final agreement.
== Clinical studies == Arsenic trioxide was clinically tested in two open-label, single-arm trials without a control group, involving 52 patients with acute promyelocytic leukemia who had previously been unsuccessfully treated with anthracyclines and retinoids. The results of these studies are presented in the table below.
=== Modulation === A neurotransmitter may have an excitatory, inhibitory or modulatory effect on the target cell. The effect is determined by the receptors the neurotransmitter interacts with at the post-synaptic membrane. Neurotransmitters influence trans-membrane ion flow either to increase (excitatory) or to decrease (inhibitory) the probability that the cell with which it comes in contact will produce an action potential. Synapses containing receptors with excitatory effects are called Type I synapses, while Type II synapses contain receptors with inhibitory effects. Thus, despite the wide variety of synapses, they all convey only these two types of messages. The two types have different appearances and primarily act on different parts of neurons. Receptors with modulatory effects are spread throughout all synaptic membranes and binding of neurotransmitters sets in motion signaling cascades that help the cell regulate its function. Binding of neurotransmitters to receptors with modulatory effects can have many results. For example, it may increase or decrease in sensitivity to future stimuli by recruiting more or fewer receptors to the synaptic membrane. Type I (excitatory) synapses are typically located on the shafts or the spines of dendrites, whereas type II (inhibitory) synapses are typically located on the cell body. In addition, Type I synapses have round synaptic vesicles, whereas the vesicles of type II synapses are flattened.
Sources: en.wikipedia.org
=== 6 December === The Governor of Kursk Oblast in Russia, Roman Starovoyt, claimed that a Ukrainian drone attack destroyed an oil tank near an airbase. No reports of casualties and the fire was under control. There was no comment from Ukraine on these claims.
LLLT uses lasers, LEDs, or a combination of both to alter biological activity. The light sources expose cells to low-levels of red and near infrared light (compared to other forms of laser therapy). LLLT makes use of the Grotthuss-Draper law, the first law in photochemistry: light must be absorbed by a chemical substance in order for a photochemical reaction to take place. In the generally accepted LLLT theory that chemical substance is represented by the respiratory enzyme cytochrome c oxidase, which is involved in the electron transport chain in mitochondria. Administering LLLT below the dose range does not appear to be effective.
== Overdose == In the event of an overdose of elagolix, the person should be monitored for any signs or symptoms of adverse reactions and should be treated on a symptomatic basis as needed. Elagolix has been assessed in clinical studies at a dose as high as a single administration of 1,200 mg, which resulted in concentrations of the medication that were 17 times higher than with the typical high clinical dosage of 200 mg twice per day. No adverse effects were mentioned. Chronic overdosage of elagolix may result in greater suppression of estradiol levels and a consequent increased risk of bone loss with long-term therapy.
Sources: en.wikipedia.org
== Function == HLA-G is a major immune checkpoint, meaning it downregulates the immune system's response. Soluble HLA-G can be found in the saliva, ascitic fluid, plasma, thymus, seminal plasma, cerebrospinal fluid, and in first and second term placentas. Membrane-bound HLA-G is predominantly found on trophoblast cells in the placenta, but it is also found in the thymus, cornea, erythroblasts, and mesenchymal stem cells. It can be upregulated in cancers. Peptides are connected to HLA-G by the peptide loading complex in the endoplasmic reticulum.
Parathyroid hormone-related protein (PTHrP) is a proteinaceous hormone and a member of the parathyroid hormone family secreted by mesenchymal stem cells. It is occasionally secreted by cancer cells (for example, breast cancer, certain types of lung cancer including squamous-cell lung carcinoma). However, it also has normal functions in bone, teeth, vascular tissues and other tissues.
The Meiji era (明治時代, Meiji jidai) was an era of Japanese history that extended from October 23, 1868, to July 30, 1912. The Meiji era dominated the first half of the Empire of Japan, when the Japanese people moved from being an isolated feudal society at risk of colonization by Western imperial powers to the new paradigm of a modern, industrialized nation state and emergent great power, influenced by Western scientific, technological, philosophical, political, legal, and aesthetic ideas. As a result of such wholesale adoption of radically different ideas, the changes to Japan were profound, and affected its social structure, culture, internal politics, economy, military, and foreign relations. The period corresponded to the reign of Emperor Meiji. It was preceded by the Keiō era and was succeeded by the Taishō era, upon the accession of Emperor Taishō following his father's death. The rapid modernization during the Meiji era was not without its opponents, as the rapid changes to society caused many disaffected traditionalists from the former Shōgun military warlords and samurai classes to rebel against the Meiji government during the 1870s, most famously Saigō Takamori, who led the Satsuma Rebellion. However, there were also former samurai who remained loyal while serving in the Meiji government, such as Itō Hirobumi and Itagaki Taisuke.
"A quick and simple introduction to Drosophila melanogaster". Drosophila Virtual Library. "Drosophila Genomics Resource Center" – collects, maintains and distributes Drosophila DNA clones and cell lines. "Bloomington Drosophila Stock Center" – collects, maintains and distributes Drosophila melanogaster strains for research "FlyBase—A Database of Drosophila Genes & Genomes". Archived from the original on November 3, 2018. Retrieved January 28, 2011. "NCBI Map Viewer – Drosophila melanogaster". Archived from the original on June 5, 2003. "Drosophila Virtual Library". "The Berkeley Drosophila Genome Project". "FlyMove". – video resources for Drosophila development "Drosophila Nomenclature—naming of genes". Archived from the original on October 8, 2011. View the Fruitfly genome on Ensembl View the dm6 genome assembly in the UCSC Genome Browser Manchester Fly Facility – for the public Archived 2015-05-13 at the Wayback Machine from the University of Manchester The droso4schools website with school-relevant resources about Drosophila Part 1 of the "Small fly: BIG impact" educational videos explaining the history and importance of the model organism Drosophila. Part 2 of the "Small fly: BIG impact" educational videos explaining how research is carried out in Drosophila. "Inside the Fly Lab"—broadcast by WGBH and PBS, in the program series Curious, January 2008. "How a Fly Detects Poison" Deprecated link archived 2013-01-13 at archive.today—WhyFiles.org article describes how the fruit fly tastes a larva-killing chemical in food.
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.